Benjamin Hohl - Dec 13, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Benjamin Hohl
Stock symbol
ELVN
Transactions as of
Dec 13, 2024
Transactions value $
$9,681
Form type
4
Date filed
1/7/2025, 04:43 PM
Previous filing
Dec 2, 2024
Next filing
Dec 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Options Exercise $32.2K +13K $2.48 13K Dec 13, 2024 Direct
transaction ELVN Common Stock Options Exercise $2.48K +1K +7.69% $2.48 14K Jan 3, 2025 Direct F1
transaction ELVN Common Stock Sale -$25K -1K -7.14% $25.04 13K Jan 3, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Options Exercise $0 -13K -7.71% $0.00 156K Dec 13, 2024 Common Stock 13K $2.48 Direct F3, F4
transaction ELVN Stock Option (right to buy) Options Exercise $0 -1K -0.66% $0.00 150K Jan 3, 2025 Common Stock 1K $2.48 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The 1,000 share option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $25.00 to $25.045. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
F4 The number of derivative securities beneficially owned following the option exercise was as of December 13, 2024 and does not reflect subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024.
F5 The number of derivative securities beneficially owned following the option exercise is as of January 3, 2025 and reflects the option exercise that occurred December 13, 2024, and reported herein, and subsequent option exercises that occurred on December 27, 2024 and December 30, 2024 as reported in a Form 4 filed by the Reporting Person on December 31, 2024